Your AI-Trained Oncology Knowledge Connection!
The ability to identify which mutations are likely to be "drivers" in cancer pathogenesis and to elucidate how mutated genes affect the biology of a given tumor are fundamental current challenges that might provide hope in cancer genomics in the future.
Even in seemingly uniform cell populations within subcompartments, cell-cell heterogeneity is becoming more evident, far beyond what was previously expected.
It has been our privilege to salute those who have contributed so richly to the remarkable ongoing progress in oncology.
Melissa A. Wilson, MD, PhD, discusses how targeted therapies and combination protocols are revolutionizing the treatment paradigm of advanced melanoma.
